Organized by: BioIncubator and TechEx.in @ V
Monday, 02 December, 2024| Time: 12:30 PM - 1:30 PM | HYBRID: In person at Lecture Theatre @ Venture Center and Online via Zoom
Highlights of the talk:
- Dr. Kannan's team has developed dendrimer-drug conjugates with significant potential for neurological, ocular, and cardiometabolic disorders, achieving groundbreaking clinical outcomes for severe COVID-19, AMD, and diabetic retinopathy
- Through extensive validation in animal models and clinical trials, the team’s innovations have spurred multiple start-ups and translational efforts in the US and India
- The talk will highlight the application of this approach in treating inflammatory, obesity, retinal, and brain disorders, and discuss recent advancements in developing innovative applications for antibody delivery
- It will also focus on the journey of transforming innovative ideas into successful start-ups, driving translational efforts and first-generation therapies in both India and the US.
About our speaker: Kannan Rangaramanujam, Ph.D. (Arnall Patz Distinguished Professor of Ophthalmology, Center for Nanomedicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA)
Event related queries: Manish Gore | +91-7410045657 | manish.gore@venturecenter.co.in
- Dr. Kannan Rangaramanujam is the Arnall Patz Distinguished Professor of Ophthalmology and Co-Director of Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins School of Medicine.
- He is a chemical engineer by training [PhD (Caltech); BE(Hons.)(BITS, Pilani)]. His research interests are in the field of translational nanomedicine centered on novel approaches to target specific cells at the site of injury.
- His team has developed and extensively validated the hydroxyl dendrimer platform through Hopkins-wide collaborations in many animal models of ocular, brain disorders, pain, depression, and cancer. These have the opportunity to address long standing challenges in the field, and will lead to medicines that are easy to administer (e.g., oral pills for AMD and diabetic retinopathy), have minimal side effects, and affordable to large fractions of the world population.
- He is leading the translation of his research to the clinic, through start-ups and partnerships.
- He is the co-founder of Ashvattha Therapeutics Inc. and Samata Therapeutics ( more than $100M raised) – Johns Hopkins spinoffs that are translating some of his team’s patented dendrimer technologies to the clinic, with three products that have completed, or in Phase 2 trials. OP-101, a product developed from his group showed significant promise in Phase 2 trials for severe COVID-19. A subcutaneous, targeted therapy for wet AMD and diabetic retinopathy is undergoing Phase 2 trials.
- Dr. Rangaramanujam is an author of more than 150 patents (issued and pending, licensed), more than 150 peer-reviewed publications, and is supported by significant NIH and federal funding.
- He has won several recognitions, including fellowship of the American Institute of Medical and Biological Engineers (AIMBE), Controlled Release Society, and Distinguished Alumni Award from BITS (Pilani).
- He is on the editorial boards of Biomaterials, Advanced Drug Delivery Reviews, and Theranostics.
The talk is free & open to all, but registration is mandatory| Register at- https://tinyurl.com/dec-talk
Note for the event:
- Organizers reserve the right to accept or refuse or delay registrations so to optimize the composition of the group and hence maximize learning for all participants
- Only registered participants will be allowed to participate in the event
- Email invitations with links to participate at the event will be sent closer to the event